On May 5, 2020 LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on developing first-in-class or best-in-class therapeutics for the treatment of orphan diseases with few or no therapeutic options, reported the appointment of Michael Huang, MD, as its Chief Medical Officer (Press release, LifeMax Laboratories, MAY 5, 2020, View Source [SID1234557052]). LifeMax has several clinical stage programs. LM-030, licensed from Novartis and with fast track designation, rare pediatric disease designation and orphan drug designation, is in a Phase 2/3 trial for the treatment of Netherton syndrome. AMB-051, licensed from Amgen through AmMax, its majority-owned subsidiary, and delivered via a patented technology, is in development as a best-in-class, well-differentiated and broadly applicable treatment for tenosynovial giant cell tumor.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very pleased to have Dr. Huang on board. Dr. Huang brings with him a wealth of experience in drug development including both small and large molecules across a diverse range of therapeutic indications, especially in orphan indications. Dr. Huang’s expertise fits very well with our portfolio of first-in-class or best-in-class therapies for orphan diseases," said Larry Hsu, LifeMax’s Co-founder and CEO, an industry veteran who previously founded and built Impax Laboratories into a publicly traded multi-billion-dollar company.
"I am delighted to join LifeMax at such an exciting time. I am very impressed with LifeMax’s management team, its strategy, and robust science-driven portfolio focused on orphan diseases that address significant unmet medical needs. I look forward to working with the team to advance our portfolio towards regulatory approval and commercialization," said Dr. Huang.
Dr. Huang was most recently Chief Medical Officer of Spruce Biosciences. He is an experienced biopharmaceutical industry executive who has successfully advanced therapeutics across modalities through all phases of development to regulatory approval. He is the author or co-author of numerous peer-reviewed journal articles, abstracts, and scientific publications. Dr. Huang received his bachelor’s degree in molecular and cell biology from the University of California at Berkeley, his medical degree from the Chicago Medical School, and his post-graduate internship and residency training from the University of California at Irvine.